Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...

A series of recent changes could have significant implications for how Americans receive and pay for their shots.

The French biotech is developing a new drug approach in a disease market that’s projected to grow to $30 billion by 2030.

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...